

Nancie M Archin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6194181/publications.pdf>

Version: 2024-02-01

47
papers

4,559
citations

136885

32
h-index

214721

47
g-index

49
all docs

49
docs citations

49
times ranked

4055
citing authors

#	ARTICLE	IF	CITATIONS
1	Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. <i>Journal of Infectious Diseases</i> , 2015, 212, 1361-1365.	1.9	362
2	An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients. <i>PLoS Pathogens</i> , 2013, 9, e1003834.	2.1	360
3	Expression of Latent HIV Induced by the Potent HDAC Inhibitor Suberoylanilide Hydroxamic Acid. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 207-212.	0.5	317
4	Eradicating HIV-1 infection: seeking to clear a persistent pathogen. <i>Nature Reviews Microbiology</i> , 2014, 12, 750-764.	13.6	247
5	Coaxing HIV-1 from resting CD4 T cells. <i>Aids</i> , 2004, 18, 1101-1108.	1.0	233
6	Systemic HIV and SIV latency reversal via non-canonical NF- κ B signalling in vivo. <i>Nature</i> , 2020, 578, 160-165.	13.7	210
7	Immediate antiviral therapy appears to restrict resting CD4 ⁺ cell HIV-1 infection without accelerating the decay of latent infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 9523-9528.	3.3	202
8	A Limited Group of Class I Histone Deacetylases Acts To Repress Human Immunodeficiency Virus Type 1 Expression. <i>Journal of Virology</i> , 2009, 83, 4749-4756.	1.5	183
9	Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. <i>Journal of Clinical Investigation</i> , 2017, 127, 3126-3135.	3.9	165
10	Emerging strategies to deplete the HIV reservoir. <i>Current Opinion in Infectious Diseases</i> , 2014, 27, 29-35.	1.3	164
11	Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. <i>Aids</i> , 2009, 23, 1799-1806.	1.0	154
12	Quantitation of Replication-Competent HIV-1 in Populations of Resting CD4 ⁺ T Cells. <i>Journal of Virology</i> , 2014, 88, 14070-14077.	1.5	146
13	Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. <i>Nature Medicine</i> , 2021, 27, 2085-2098.	15.2	146
14	The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	141
15	Curing HIV: Seeking to Target and Clear Persistent Infection. <i>Cell</i> , 2020, 181, 189-206.	13.5	126
16	Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. <i>Journal of Clinical Investigation</i> , 2015, 125, 4077-4090.	3.9	124
17	HIV latency is reversed by ACSS2-driven histone crotonylation. <i>Journal of Clinical Investigation</i> , 2018, 128, 1190-1198.	3.9	109
18	Targeted Cytotoxic Therapy Kills Persisting HIV Infected Cells During ART. <i>PLoS Pathogens</i> , 2014, 10, e1003872.	2.1	101

#	ARTICLE	IF	CITATIONS
19	Expanded Cytotoxic T-cell Lymphocytes Target the Latent HIV Reservoir. <i>Journal of Infectious Diseases</i> , 2015, 212, 258-263.	1.9	86
20	Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation. <i>Cell Reports</i> , 2017, 18, 1324-1334.	2.9	69
21	Peripheral VÎ³VÎ² T Cells Are a Novel Reservoir of Latent HIV Infection. <i>PLoS Pathogens</i> , 2015, 11, e1005201.	2.1	66
22	Selective HDAC Inhibition for the Disruption of Latent HIV-1 Infection. <i>PLoS ONE</i> , 2014, 9, e102684.	1.1	65
23	Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir. <i>ELife</i> , 2020, 9, .	2.8	63
24	H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in <i>Ex Vivo</i> Cultures of Resting CD4 ⁺ T Cells. <i>Journal of Virology</i> , 2015, 89, 8392-8405.	1.5	60
25	HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal. <i>JCI Insight</i> , 2017, 2, .	2.3	59
26	Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells. <i>Clinical Infectious Diseases</i> , 2019, 69, 1345-1352.	2.9	58
27	Longitudinal Dynamics of Intact HIV Proviral DNA and Outgrowth Virus Frequencies in a Cohort of Individuals Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2021, 224, 92-100.	1.9	57
28	In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection. <i>Retrovirology</i> , 2016, 13, 36.	0.9	54
29	Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA. <i>Journal of Virology</i> , 2021, 95, .	1.5	47
30	Broadly-specific Cytotoxic T Cells Targeting Multiple HIV Antigens Are Expanded From HIV+ Patients: Implications for Immunotherapy. <i>Molecular Therapy</i> , 2015, 23, 387-395.	3.7	46
31	New Frontiers in Measuring and Characterizing the HIV Reservoir. <i>Frontiers in Microbiology</i> , 2019, 10, 2878.	1.5	43
32	<i>Staphylococcus aureus</i> Infection in Humanized Mice: A New Model to Study Pathogenicity Associated With Human Immune Response. <i>Journal of Infectious Diseases</i> , 2015, 212, 435-444.	1.9	36
33	HIV and women in the USA: what we know and where to go from here. <i>Lancet, The</i> , 2021, 397, 1107-1115.	6.3	35
34	HIV-Specific, <i>Ex Vivo</i> Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals. <i>Molecular Therapy</i> , 2018, 26, 2496-2506.	3.7	32
35	Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection. <i>Scientific Reports</i> , 2020, 10, 5134.	1.6	32
36	SLDAssay: A software package and web tool for analyzing limiting dilution assays. <i>Journal of Immunological Methods</i> , 2017, 450, 10-16.	0.6	27

#	ARTICLE	IF	CITATIONS
37	The HIV-1 latent reservoir is largely sensitive to circulating T cells. <i>ELife</i> , 2020, 9, .	2.8	25
38	Impact of Biological Sex on Immune Activation and Frequency of the Latent HIV Reservoir During Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 222, 1843-1852.	1.9	22
39	Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat. <i>Journal of Infectious Diseases</i> , 2022, 225, 856-861.	1.9	22
40	Evaluation of EED Inhibitors as a Class of PRC2-Targeted Small Molecules for HIV Latency Reversal. <i>ACS Infectious Diseases</i> , 2020, 6, 1719-1733.	1.8	17
41	Combined noncanonical NF- κ B agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	17
42	Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, 1389-1396.	2.9	9
43	Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat. <i>Journal of Virology</i> , 2020, 94, .	1.5	6
44	Crotonylation sensitizes IAPi-induced disruption of latent HIV by enhancing p100 cleavage into p52. <i>IScience</i> , 2022, 25, 103649.	1.9	6
45	Defining Stable Reference Genes in HIV Latency Reversal Experiments. <i>Journal of Virology</i> , 2021, 95, .	1.5	5
46	Immunological Correlates of the HIV-1 Replication-Competent Reservoir Size. <i>Clinical Infectious Diseases</i> , 2021, 73, 1528-1531.	2.9	4
47	Reliable Estimation of CD8 T Cell Inhibition of In Vitro HIV-1 Replication. <i>Frontiers in Immunology</i> , 2021, 12, 666991.	2.2	1